Clinical Trial Update: Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating modified short-course radiotherapy followed by tislelizumab plus CAPOX for locally advanced rectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Mid-low Rectal Cancer | Phase 2 | Status: COMPLETED